Recherche
Résultats 1-10 de 61
-
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
The Lancet. Oncology, 2015, 16, 704-715Article dans une revue scientifique -
Radioimmunotherapy (Y-90-Ibritumomab Tiuxetan) for Posttransplant Lymphoproliferative Disorders After Prior Exposure to Rituximab
American journal of transplantation, 2015, 15, 1976-1981Article dans une revue scientifique -
Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes
Leukemia, 2015, 29, 1578-1586Article dans une revue scientifique -
An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma
Clinical cancer research, 2015, 21, 1843-1850Article dans une revue scientifique -
Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphoma
Br. J. Haematol., 2015, 170, 285-287Article dans une revue scientifique -
MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome
Br. J. Haematol., 11-07-2015, 167, 506-513Article dans une revue scientifique -
Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B)
Ann. Oncol., 11-07-2015, 24, 1032-1037Article dans une revue scientifique -
A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma
Ann. Oncol., 11-07-2015, 23, 2687-2695Article dans une revue scientifique -
Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma
Leukemia, 11-07-2015, 27, 252-255Article dans une revue scientifique -
Upfront Consolidation Combining Yttrium-90 Ibritumomab Tiuxetan and High-Dose Therapy with Stem Cell Transplantation in Poor-Risk Patients with Diffuse Large B Cell Lymphoma
Biol. Blood Marrow Transplant., 11-07-2015, 20, 1905-1911Article dans une revue scientifique